US EditionPublished • loading... • Updated
Natus announces FDA 510(k) clearance for electrographic status epilepticus diagnostic indication in BrainWatch point-of-care EEG solution
BrainWatch's new FDA-cleared technology enables rapid seizure diagnosis and may qualify for a $913.90 New Technology Add-on Payment, improving critical care interventions.
Summary by PR Newswire
9 Articles
9 Articles
Farm Talk Newspaper+8 Reposted by 8 other sources
Natus announces FDA 510(k) clearance for electrographic status epilepticus diagnostic indication in BrainWatch point-of-care EEG solution
MIDDLETON, Wis., Dec. 3, 2025 /PRNewswire/ -- Natus Medical Incorporated announced the electrographic status epilepticus diagnosis capability of its BrainWatch point-of-care EEG solution, featuring integrated Persyst analysis software which has received 510(k) clearance from the U.S. Food and Drug Administration.
·Parsons, United States
Read Full ArticleCoverage Details
Total News Sources9
Leaning Left0Leaning Right0Center5Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
